Chromosomal locus 15q25, implicated in lung cancer risk and nicotine dependence, shows extensive linkage disequilibrium that complicates identification of causal variation. Cholinergic receptor nicotinic a5 (CHRNA5) has been identified as a lung cancer risk factor. We identified by sequence analysis three haplotypes (delTTC, insATC, and insTGG) in the 5′ promoter region and three at the 3′-untranslated region of CHRNA5. Linkage disequilibrium analysis of the 5′ variants showed that the insTGG haplotype is associated with three tightly linked risk alleles (nicotine dependence, lung cancer, and chronic obstructive pulmonary disease). The three CHRNA5 promoter haplotypes were statistically significantly associated with lung CHRNA5 transcript levels, determined by real-time polymerase chain reaction. In nontumor lung parenchyma from 68 patients who underwent lung lobectomy, the delTTC haplotype was associated with the highest CHRNA5 transcript levels (relative quantification units = 1.82), whereas the insTGG haplotype was associated with the lowest (0.88 units, P diff < .001, Welch t test; all statistical tests were two-sided). Luciferase reporter assays in human lung cancer cell lines A549, H460, H520, and H596 also showed that the 5′ region haplotypes were statistically significantly associated with changes in CHRNA5 promoter activity, whereas the 3′-untranslated region variants were not.
relative quantification [RQ] = 1.72) CHRNA5 mRNA levels and 10 samples with low (mean RQ = 0.53) CHRNA5 mRNA levels (6) were amplified by polymerase chain reaction for the 5′ region and 3′-UTR of CHRNA5 (using primer pairs listed in Supplementary Table 1, available online) and sequenced using an automated sequencer (Applied Biosystems, Foster City, CA). Sequences were aligned and compared using Genomatix Dialign software (http:// www.genomatix.de).
Sequence analysis of the CHRNA5 5′ region identified SNP rs3841324, an insertion/deletion (ins/del) of 22 base pairs, at position 271 upstream of the transcription start site, as well as three known SNPs: rs503464 mapping at 210, and rs55853698 and rs55781567 mapping at the 5′-UTR. We found that the four variations of the CHRNA5 5′ region defined three haplotypes, delTTC, insATC, and insTGG.
SNPs validated in our samples were genotyped in 68 samples previously analyzed (6) for CHRNA5 mRNA levels using either 3% agarose gel electrophoresis (rs3841324) or pyrosequencing analysis on a PSQ96MA system (Biotage AB, Uppsala, Sweden) according to the manufacturer's instructions (using specific primers listed in Supplementary Table 1, available online). Haplotype analysis showed that in nontumor lung parenchyma, the delTTC haplotype was associated with the highest CHRNA5 transcript levels (RQ = 1.82), whereas the insTGG haplotype was associated with the lowest (RQ = 0.88, difference = 0.94 units, 95% confidence interval [CI] = 0.62 to 1.27, P diff < .001, two-sided Welch t test; Table 1 ). Diplotype analysis also showed that individuals homozygous or heterozygous for the delTTC haplotype expressed higher CHRNA5 mRNA levels than reference insTGG homozygous subjects (Figure 1, A) .
To place the CHRNA5 promoter haplotypes in the context of the linkage disequilibrium pattern in the 15q25 locus, we evaluated the linkage of the promoter haplotypes with SNP rs16969968 (Asp398Asn) and two other SNPs reportedly associated with nicotine dependence (9), lung cancer (1), and chronic obstructive pulmonary disease (4) . Analysis of the HapMap (www .hapmap.org; accessed October 30, 2009) Several genetic variants at chromosomal locus 15q25, including cholinergic receptor nicotinic a5 (CHRNA5), were found to be associated with lung cancer risk and nicotine dependence in recent genome-wide association studies (1-3). The same alleles were also associated with increased risk of chronic obstructive pulmonary disease (4, 5) .
In a previous study (6), we observed increased CHRNA5 transcript levels in lung adenocarcinomas and showed a statistically significant association between the Asn398 variant of the single-nucleotide polymorphism (SNP) rs16969968 of CHRNA5 and lower transcript levels of this gene in normal lung tissue. Fine mapping and expression analysis in human brain tissue also pointed to the candidacy of CHRNA5 as a risk factor for nicotine dependence and lung cancer (7) . Nonetheless, the strong linkage disequilibrium among all CHRNA5 variants complicates assignment of any biological role to a specific variant (1) (2) (3) . Among these variants, the SNP rs3841324 showed the highest association with CHRNA5 mRNA levels in both brain and lung tissue (7, 8) .
To unravel the functional variation responsible for modulation of CHRNA5 expression, we integrated genetic information of the 5′-and 3′-untranslated regions (UTR) with expression levels of CHRNA5 in nontumor lung parenchyma of 68 patients who underwent lung lobectomy. Study protocols were approved by the Istituto Nazionale Tumori ethics committee, and written informed consent was obtained from each subject for use of biological material.
To identify genetic polymorphisms associated with CHRNA5 mRNA levels and in linkage disequilibrium with the Asp398Asn polymorphism, genomic DNA of 10 normal lung samples with high (mean genotyping data of the rs16969968 (Asp398Asn), rs8034191, and rs1051730 in a population of US (Utah) residents of northern and western European ancestry (n = 165) showed that they are in tight linkage disequilibrium [D′ = 1.0, r 2 = 0.89-1.0, JLIN, version 1.6.0, http://www.genepi .org.au/jlin.html, accessed October 30, 2009 (10)]. We found that insTGG is linked to the Asn398 risk allele, which is strongly associated with the C (rs8034191) and T (rs1051730) risk alleles, whereas delTTC and insATC are linked to the conteXtS anD caVeatS
Prior knowledge
Cholinergic receptor nicotinic a5 (CHRNA5) is located in chromosomal locus 15q25, which has been associated with the risk of lung cancer and nicotine dependence. However, identification of polymorphisms at this chromosomal region is difficult because of extensive linkage disequilibrium.
Study design
Sequence analysis revealed three variants in the 5′ promoter region and three at the 3′-untranslated region of CHRNA5. The association between these polymorphisms and CHRNA5 expression levels was examined with real-time polymerase chain reaction of RNA from normal lung tissue of lung cancer patients and with luciferase reporter assays in four lung cancer cell lines.
Contribution
The three promoter variants were associated with statistically significant differences in CHRNA5 expression and luciferase activity, but the variants at the 3′-untranslated region were not.
Implications
Polymorphisms in the CHRNA5 promoter region may modify the binding sites for transcription factors, which can alter CHRNA5 expression levels and the risk of nicotine dependence, lung cancer, and chronic obstructive pulmonary disease.
Limitations
A limitation of the study was that the modulation of CHRNA5 expression by the three promoter haplotypes was consistent between the lung tissue samples and one of the four human lung cancer cell lines but varied in three others. Table 1 . Association of the specific haplotypes in the cholinergic receptor nicotinic a5 respectively. ‡ Number of chromosomes containing a specific CHRNA5 promoter haplotype, estimated using the PHASE program (68 patients, total of 136 chromosomes) distributed according to the allele carrier status of the Asp398Asn variant. The PHASE program (v2.1.1; Matthew Stephens, The University of Chicago, Chicago, IL; http://www.stat.washington.edu/stephens/software.html), which implements a method for reconstructing haplotypes from population data using a type of Markov chain Monte Carlo algorithm, allowed an unambiguous haplotype reconstruction in 68 patients, with a probability of reconstruction = 1.0. § Mean relative quantification (RQ) of mRNA levels associated with chromosomes containing the indicated haplotype. ║ Calculated with two-sided Welch t test. ¶ The Asn398 allele was tightly linked to the C and T alleles of rs8034191 and rs1051730, respectively, which are associated with a higher risk of nicotine dependence (9), lung cancer (1), and chronic obstructive pulmonary disease (4), as compared with their reference alleles. Single-nucleotide polymorphisms were genotyped using either 3% agarose gel electrophoresis (rs3841324) or pyrosequencing analysis on a PSQ96MA system (Biotage AB) using specific primers (Supplementary  Table 1 , available online). Total RNA was extracted from nontumor lung parenchyma using the RNeasy Midi kit (Qiagen, Valencia, CA) and reverse transcribed using the ThermoScript RT-PCR system (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. CHRNA5 mRNA levels were analyzed by quantitative real-time polymerase chain reaction using TaqMan Gene Expression Assays (Hs00181248_m1, Applied Biosystems), as described previously (6) . The human hypoxanthine phosphoribosyltransferase 1 gene (Hs99999909_m1) was used as housekeeping control. Relative quantification (RQ) represents normalized expression units assessed using the comparative Ct method and a pool of normal lung tissue as calibrator. The heavy line within each box represents the median RQ value (in log 2 -transformed units); upper and lower edges of each box represent the 75th and 25th percentile, respectively; upper and lower bars indicate the highest and lowest values determined, respectively. Asterisks denote statistically significant differences by comparison with the homozygous carriers of the insTGG haplotype, used as reference (mean RQ and number of samples (n) of the diplotypes were: insTGG/insTGG, 20.75, n = 22; insTGG/ insATC, 20.25, n = 12; insTGG/delTTC, 0.38, n = 13; insATC/insATC, 20.32, n = 2; insATC/delTTC, 0.23, n = 10; delTTC/delTTC, 1.14, n = 9; P < .001, overall). Differences in mean normalized expression units between patients with insTGG/delTTC, insATC/delTTC, and delTTC/delTTC diplotypes and patients with the insTGG/insTGG diplotype were 0. Asp398 allele (Table 1) . Therefore, risk alleles for nicotine dependence (9), lung cancer (1), and chronic obstructive pulmonary disease (4) are associated with the insTGG haplotype, which is associated with low levels of CHRNA5 mRNA in normal lung tissue (RQ = 0.88; Table 1 ). The functional role of the three 5′ region haplotypes was investigated by subcloning 732 base pairs of the proximal promoter into the pGL3-Basic vector upstream of the ATG of the firefly luciferase gene, used as primary reporter to monitor changes in mRNA (Figure 1, B) . The respective vectors were transfected together with the Renilla luciferase pRL-TK reporter vector into four lung cancer cell lines (A549, NCI-H460, NCI-H520, and NCI-H596, purchased from American Type Culture Collection, Manassas, VA and passaged three to four times) for analysis by Dual-Luciferase Reporter Assay (Promega, Madison, WI), 48 hours after transfection. Signals were normalized to Renilla luciferase activity and expressed as relative luciferase activity. Data from three replicates of two independent experiments were evaluated (Figure 1 , C, and Supplementary Table 2, available online).
From the Editors
Overall, the normalized firefly/Renilla luciferase activity of the three recombinant vectors was increased 94-fold as compared with that of the empty control vector (mean luciferase activity, relative units: recombinant vectors, 1.33; empty control vector, 0.01, difference = 1.31, 95% CI diff = 1.26 to 1.36, P diff < .001, two-sided Welch t test), indicating in vitro functional activity of the CHRNA5 promoter.
Luciferase activity was differentially modulated by the insATC and delTCC promoter haplotypes, as compared with the reference insTGG haplotype (Supplementary  Table 2 , available online). In A549 cells, both the insATC and the delTCC haplotypes showed a statistically significant increase of CHRNA5 promoter activity (P diff ≤ .003, two-sided Welch t test); in NCI-H460 and NCI-H520 cells, the insATC haplotype increased CHRNA5 promoter activity (P = .001), whereas the delTCC haplotype produced a strong decrease (P diff ≤ .001). Finally, in H596 cells, the reference insTGG haplotype showed about the same promoter activity as the insATC haplotype and the delTCC haplotype showed statistically significantly decreased activity (P diff = .002, Figure 1 , C, and Supplementary Table 2 , available online).
Sequence analysis of the CHRNA5 3′-UTR revealed three known SNPs (rs615470, rs8192482 and rs564585), which distinguished three haplotypes, CTA, CCG, and TCA. The same four lung cancer cell lines were transfected with the 3′-UTR subcloned into the pmirGLO vector downstream of the firefly luciferase gene (Figure 1, D) . The normalized firefly/Renilla luciferase activities of the three different haplotypes were compared with each other and with the empty control vector and revealed an overall modest effect of the 3′-UTR on firefly luciferase activity in all cell lines, with a decreased activity in A549 and NCI-H460 cells and increased activity in NCI-H520 and NCI-H596 cells (Figure 1 , E). Whereas these results do not rule out a minor role for the 3′-UTR in modulating CHRNA5 mRNA levels, luciferase activity did not differ statistically significantly among the three 3′-UTR haplotypes in any of the cell lines, except for a small difference between the CCG (mean luciferase activity, 20.02 units) and TCA (mean, 20.21 units) haplotypes in NCI-H460 cells (difference, 0.19 units, 95% CI diff = 0.08 to 0.29, P diff = .003, two-sided Welch t test).
Because CHRNA5 lies in a tail-to-tail orientation with respect to CHRNA3 and partially overlaps with CHRNA3, we explored the role of CHRNA3 as a possible antisense regulator by determining with reverse transcription-polymerase chain reaction and sequence analysis which transcripts of CHRNA5 and CHRNA3 were expressed in lung tissue. The expression of the two known CHRNA5 and four known CHRNA3 transcripts, described in the Ensembl database (www.ensembl.org; accessed on December 24, 2008), was checked in normal lung tissue (primer pairs listed in Supplementary Table 1, available online) with BIO-X-ACT Short DNA Polymerase (BIOLINE, London, UK). Of the two known CHRNA5 transcripts, only ENST00000299565 was detected, whereas the shorter transcript (ENST00000394802) was not polymerase chain reaction amplified. Polymerase chain reaction analysis of the four CHRNA3 transcripts detected only ENST00000326828, ENST00000394793, and an as yet undescribed shorter CHRNA3 transcript (330 base pairs), resulting from an alternative splice that skipped exon 2 of the ENST00000394793 variant. These two latter CHRNA3 transcripts overlap exon 6 of CHRNA5 (Supplementary Figure 1, vectors containing the CHRNA5 promoter or the 3′-untranslated region (UTR). Arrows indicate the position of the different polymorphisms mapping in the 5′ region, 5′-UTR, or the 3′-UTR. Genomic DNA was PCR-amplified for the 5′ region and 3′-UTR of CHRNA5 using primer pairs reported in Supplementary Table 1 (available online) and sequenced using an automatic sequencer (Applied Biosystems). Genomic DNA selected for the three different haplotypes located in the 5′ region or 3′-UTR of the CHRNA5 ENST00000299565 transcript was amplified for the 5′ region (732 base pairs from ATG) or for the 3′-UTR using BIO-X-ACT Short DNA Polymerase (BIOLINE). PCR-amplified fragments were cloned into pGL3-Basic or pmirGLO vectors (Promega) upstream (5′ region) or downstream (3′-UTR) of the firefly luciferase reporter gene using Rapid DNA Dephos and Ligation Kit (Roche Diagnostics, Mannheim, Germany). C and E) Effects of CHRNA5 5′ region or 3′-UTR haplotypes on luciferase activity. Firefly luciferase was used as primary reporter to monitor mRNA levels, whereas Renilla luciferase served as control reporter for normalization. The Renilla gene is included in pmirGLO vectors, whereas pGL3-Basic vectors were cotransfected with the pRL-TK plasmid (Promega). Cells were assayed for luciferase activity 48 hours after transfection with the Dual-Luciferase Reporter Assay System kit (Promega). C) Effect of insATC and delTCC promoter haplotypes on luciferase activity compared with the reference insTGG haplotype in A549, H460, H520, and H596 human lung cancer cell lines. Values are the mean log 2 of the normalized firefly/Renilla luciferase signal. Error bars = SE. Data of three replicates of two independent experiments were evaluated (Supplementary Table 2 , available online). Asterisks indicate statistically significant differences (P < .005, by two-sided Welch t test) as compared with cells transfected with the recombinant plasmid containing the insTGG haplotype. E) Effect of 3′-UTR haplotypes CTA, CCG, and TCA on luciferase activity. available online). NCI-H460 and NCI-H520 cells cotransfected with pmirGLO vectors containing CHRNA5 exon 6 and with the pEF6/V5-His vector expressing either of the two full-length CHRNA3 transcripts (ENST00000394793 and the new shorter transcript) showed no modulation of luciferase activity with respect to the three haplotypes as compared with activity associated with the empty pEF6/V5-His vector (not shown). Thus, interactions between CHRNA5 and CHRNA3 transcripts do not appear to play a role in CHRNA5 transcriptional control. Our in vivo and in vitro results point to the critical role of polymorphisms in the promoter region of CHRNA5 for regulation of transcription. Such polymorphisms can modify the binding sites for transcription factors whose expression levels may change in different cell types, tissues, and pathological conditions. Accordingly, one limitation of the study was that in A549 cells, the promoter haplotypes modulated the CHRNA5 transcriptional activity as observed in vivo, whereas in the other three lung cancer cell lines, the in vitro effects of promoter activity did not parallel the in vivo findings (Figure 1, A and C) . It may be possible to explain the discrepancies among cell types by analyzing the activity of different transcription factors acting on the CHRNA5 promoter.
This study identified four genetic variations in the CHRNA5 promoter region that define three haplotypes affecting activity of the promoter of this gene, thus modulating CHRNA5 transcript levels in normal lung tissue. The relationship of these promoter polymorphisms to the mechanisms underlying the risk of nicotine dependence, lung cancer, and chronic obstructive pulmonary disease awaits further study.
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Supplementary data can be found at http:// www.jnci.oxfordjournals.org/. 
